+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new dental device made of zirconia, cemented with Polymethyl methacrylate PMMA bone cement, to explore if it can serve as an additional option for replacing missing teeth. This clinical trial aims to find a faster and possibly more affordable treatment for edentulism, addressing some shortcomings of conventional bridges and dental implants. The study is an early phase interventional trial focusing on fixed prosthodontics. The trial involves placing the zirconia dental device in edentulous areas of the jaw in 48 participants. The device will be cemented with PMMA bone cement and immediately loaded within 0 to 15 days using single crowns or multiple unit bridges made of zirconia, fixed with luting cement. Participants will be randomly assigned to groups based on the location of their missing teeth maxillary anterior, maxillary posterior, mandibular anterior, or mandibular posterior regions. Participants will undergo a Cone Beam Computed Tomography CBCT scan and clinical evaluation before treatment. After device placement, clinical examinations and radiographic evaluations will be conducted every three months for one year to monitor outcomes like bone loss, gum health, oral hygiene, pain, discomfort, dislodgment, and fractures of the dental device. The entire trial spans 16 months, including follow-up periods to assess device performance and safety.

Age: 18Years - 80YearsAll GendersEarly Phase 1
1 location
P

Actively Recruiting

Researchers are evaluating the antiviral effects of various treatments in adults aged 18 to 60 with early symptomatic influenza. This phase 2, multi-centre, adaptive platform trial compares several licensed influenza antiviral drugs and others with potential activity against the virus. The study aims to provide clear comparisons of antiviral activity to help guide treatment decisions and policy development. Participants may receive one of several antiviral drugs such as oseltamivir, favipiravir, zanamivir, baloxavir, molnupiravir, peramivir, laninamivir, or combinations of these medications. There is also a control group that receives no antiviral treatment except paracetamol for fever. Dosages and administration routes vary by drug and include oral, inhaled, and intravenous methods. The trial uses randomization to assign treatments, with at least 20% of participants assigned to the no treatment group. During the first five days, researchers will monitor the rate of viral clearance to assess antiviral activity. Additional measures include symptom relief and fever duration over 14 days. Participants will be closely followed up, with assessments including rapid antigen or PCR tests for influenza, symptom tracking, and safety monitoring. The total study period covers initial treatment and observation up to two weeks after starting treatment.

Age: 18Years - 60YearsAll GendersPhase 2
4 locations
C

Actively Recruiting

This research aims to compare the effects of two blood-thinning medications, rivaroxaban and warfarin, in patients who develop a blood clot in the left ventricle of the heart after a heart attack. The study focuses on people who had a delayed hospital visit after their heart attack, a common issue in some regions, which increases the risk of such clots and related complications. The goal is to find out which medication better helps dissolve the clot and is safer to use. Participants will be randomly assigned to receive either rivaroxaban or warfarin. Those in the rivaroxaban group will take 15 to 20 mg doses depending on kidney function once daily with an evening meal. The warfarin group will start at 5 mg daily, adjusted to keep blood clotting levels within a target range, monitored by regular blood tests called INR. The study will last for three months, with follow-up visits scheduled to monitor treatment effects and any side effects. During the study, participants will undergo cardiac MRI scans to check if the blood clot has resolved after three months. Researchers will also monitor for major bleeding events and any embolic complications. Data will be securely collected and analyzed to assess the safety and effectiveness of both treatments. The study includes safety oversight by an independent board and plans to share findings through scientific publications and conferences.

Age: 18Years +All GendersPhase 4
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a mobile health mHealth behavioral intervention called TelTex4BP for adults with hypertension in Nepal. The study aims to improve blood pressure control and reduce the risk of cardiovascular disease CVD by delivering lifestyle counseling through phone calls and text messages. This hybrid type 2 effectiveness-implementation randomized controlled trial involves patients, their families, and healthcare providers to tailor the intervention to local culture and needs. Participants in the intervention group will receive structured counseling on healthy diet, physical activity, smoking, alcohol intake, medication adherence, and follow-up reminders via monthly phone calls and 2-3 text messages per week for six months. The control group will receive usual care including antihypertensive medication prescriptions, follow-up advice, and an informational pamphlet. Follow-up assessments will occur at six and twelve months to evaluate both short-term and long-term effects. Throughout the study, participants will undergo blood pressure measurements, assessments of 10-year CVD risk, medication adherence, dietary habits, and physical activity. Researchers will also evaluate how well the intervention is adopted and maintained using the RE-AIM framework. The total participation includes the six months of intervention and six months of follow-up to monitor sustainability and effectiveness of the mHealth support.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating antiviral treatments for adults with early symptomatic COVID-19 who have high viral loads but are at low risk of severe illness. This Phase 2 trial aims to develop and validate a way to measure how well these treatments reduce the amount of virus in the body. The study compares three types of interventionssmall molecule drugs, monoclonal antibodies, and dose adjustments for nirmatrelvirritonaviragainst a control group that receives no antiviral treatment. The trial is adaptive and is supported by the Wellcome Trust through the COVID-19 Therapeutics Accelerator. The treatments studied include various small molecule drugs like nitazoxanide, nirmatrelvirritonavir, hydroxychloroquine, atilotrelvirritonavir, metformin, and monoclonal antibodies such as sotrovimab and others as they become available. Some treatment arms have been closed after meeting stopping criteria. Participants are randomly assigned to receive one of the available antiviral drugs or no treatment, with at least 20% assigned to the control group. Dosages vary by drug and are typically administered over 5 to 7 days. Participants will be monitored closely over the first 14 days, with daily assessments of viral levels and symptoms. Researchers will measure how quickly the virus clears from the body compared to no treatment or positive control arms. Additional outcomes include fever resolution and symptom improvement. Participants must be able to walk unaided and agree to follow-up visits. The study runs until January 2027 and aims to determine optimal dosing and antiviral effectiveness in early COVID-19 infection.

Age: 18Years - 60YearsAll GendersPhase 2
7 locations
S

Actively Recruiting

The ICU-related Out-of-Pocket Expenses ICOPE study is a multinational, prospective observational study conducted in African and Asian countries to understand the financial impact of ICU care on patients and their families. The study focuses on measuring out-of-pocket expenses and the occurrence of catastrophic health expenditure among patients who stay in the ICU for more than 24 hours, including those who receive mechanical ventilation and those who do not. The study addresses the rising cost burden related to ICU care in low- and middle-income countries LMICs and aims to identify factors contributing to financial hardship. Participants include all patients admitted to participating ICUs during a 14-day recruitment period, with a planned sample size of at least 354 patients. The study compares groups of patients receiving invasive mechanical ventilation with those who do not, tracking their ICU-related expenses. The follow-up period extends from ICU admission to discharge, with additional assessments at 30 days and 6 months, spanning a total study duration of 18 months. During the study, researchers will collect detailed information about direct and indirect costs associated with ICU care, including medical and non-medical expenses. They will also examine how families cope with these costs and identify risk factors for catastrophic health expenditure. The primary outcomes include out-of-pocket cost per patient episode and the relative risk of catastrophic health expenditure by ICU discharge. Secondary outcomes include risk factors for catastrophic expenditure and the frequency of various coping strategies used by families.

All AgesAll Genders
44 locations
E

Actively Recruiting

This research aims to evaluate the use of a lower INR target range 1.5 to 2.5 in patients who have a mechanical bileaflet heart valve implanted in the aortic position. The goal is to determine whether lowering the INR target can reduce bleeding risks without increasing the chance of blood clots or stroke. This study is important for patients who require lifelong warfarin treatment to prevent clot formation on their mechanical heart valves. Participants will be randomly assigned to one of two groups one group will have their warfarin dosing adjusted to maintain an INR target between 1.5 and 2.5, while the other group will follow the standard INR target range as currently recommended. Warfarin therapy is the main intervention, and the study compares these two INR target ranges to assess outcomes related to clotting and bleeding. Treatment and follow-up are expected to last about 2 to 3 years. Throughout the study, participants will be monitored for occurrences of thrombosis, thromboembolism, major and minor bleeding, strokes, heart attacks, and other complications. Researchers will track time spent in the therapeutic INR range and the incidence of extreme INR values. Safety and effectiveness assessments will continue through the study completion, which is anticipated to be approximately 2 to 3 years after enrollment.

Age: 18Years +All GendersPhase 3
45 locations
M

Actively Recruiting

Hypertensive disorders during pregnancy HDP and gestational diabetes GDM are common complications that can cause serious health problems for mothers and babies. Researchers are studying the MOM-HD program, a mobile app-based telemonitoring system, to see if it helps women with HDP and GDM manage their blood pressure and blood glucose better. This study is a randomized controlled trial conducted in real-world hospital settings in Nepal, aiming to assess both the effectiveness and how well the program can be implemented in clinical care. The MOM-HD program includes training for patients and their families, provision of blood pressure monitors and glucometers, and a mobile app for uploading daily readings. Participants also have biweekly tele-visits with nurses who review their data and provide counseling. The study compares standard antenatal care alone to standard care plus the MOM-HD program, from enrollment during pregnancy up to 6 weeks after delivery. The program also involves ongoing technical support, financial assistance for home monitoring, and provider feedback to support sustained use. Participants will be followed from 24 to 30 weeks of pregnancy until 6 weeks postpartum. Researchers will monitor clinical outcomes such as blood pressure and blood glucose levels, and adverse perinatal events like neonatal intensive care admissions and cesarean deliveries. The study collects data through the app and provider portal, with regular telehealth check-ins, and evaluates implementation success and costs. Total participation lasts from enrollment in late pregnancy through the postpartum period, allowing comprehensive assessment of both health and program impact.

Age: 18Years +FEMALEPhase Not Applicable
3 locations
N

Actively Recruiting

This research aims to evaluate how nurse-led interventions affect self-care adherence and quality of life in adults undergoing hemodialysis for chronic kidney disease. Hemodialysis patients often face challenges like fluid and electrolyte imbalances, multiple symptoms, and mental health issues such as anxiety and depression, all of which can affect their quality of life. The study compares a nurse-led educational program combined with reminders and self-care booklets against usual care to assess improvements in patient adherence and well-being. Participants are divided into two groups one receives nurse-led interventions consisting of four laptop-based educational and counseling sessions spread over 7 to 8 weeks, weekly reminder calls on non-dialysis days, and a self-care booklet. The control group receives usual care including routine doctor rounds and advice. The intervention covers kidney function education, diet and fluid recommendations, physical activity guidance, and mental health strategies. Follow-up assessments occur at 4 and 6 months from baseline. During the study, participants undergo clinical evaluations including measurement of interdialytic weight gain, blood pressure, and body mass index from medical records. Self-care adherence is assessed through interviews using tailored questionnaires and the International Physical Activity Questionnaire. Quality of life is measured with the Kidney Disease Quality of Life Questionnaire. Data are analyzed for differences between groups at baseline, 4 months, and 6 months. The study spans several months with ongoing monitoring of patient adherence and health outcomes.

Age: 18Years - 69YearsAll GendersPhase Not Applicable
2 locations
O

Actively Recruiting

Researchers are investigating how high blood sugar levels hyperglycemia affect short- and long-term outcomes in patients who come to the emergency department with acute strokes, also known as cerebrovascular accidents CVAs. This prospective cohort study aims to understand the connection between blood sugar levels at stroke onset and the rates of death and disability over one year. By studying this relationship, the research hopes to improve care and quality of life for stroke patients. The study will include 60 patients admitted to the emergency department with acute stroke, divided evenly between those with high blood sugar and those with normal levels. Researchers will use clinical assessments, blood glucose tests, and CT scans to confirm stroke diagnosis and severity. Participants will be followed up at 1 month, 3 months, and 12 months to monitor mortality and functional outcomes using tools like the Modified Rankin Score. The study uses a systematic random sampling method to select participants. During the year-long study, data will be gathered through chart reviews and face-to-face interviews at set intervals. Researchers will record vital signs, medical history, stroke type, and neurological scores, alongside blood glucose and imaging results. Statistical analyses will help identify factors linked to mortality and morbidity. This structured approach ensures accurate monitoring of patients health and helps clarify how hyperglycemia impacts stroke recovery and survival over time.

Age: 18Years +All Genders
2 locations

1-10 of 18

1